John Latham - Alder Biopharmaceutica Insider

ALDR -- USA Stock  

USD 18.00  0.30  1.64%

Dr. John A. Latham, Ph.D., is Chief Scientific Officer of the Company. Dr. Latham served as a director, senior director, and most recently as Vice President of Gene Function and Target Validation for Celltech Group plc. In 1994, Dr. Latham joined Darwin Molecular Corporationrationration, a firstgeneration genetodrug biotechnology company, as a founding director, where he served from 1994 to 1998. Dr. Latham was one of the early scientists hired by Gilead Sciences, Inc., a biopharmaceutical company, and, from 1989 to 1994, he was a member of a core group established to exploit novel oligonucleotidebased technologies
Age: 56    Ph.D    
Latham holds a Ph.D. in Biochemistry from Massachusetts Institute of Technology and a B.S. in Chemistry from Colorado State University.

John Latham Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of (37.62) % which means that it has lost $37.62 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (80.13) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 173.2 M in liabilities with Debt to Equity (D/E) ratio of 43.2 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Alder Biopharmaceuticals has Current Ratio of 13.04 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Entity Summary

Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington. Alder Biopharmaceutica operates under Biotechnology classification in USA and traded on BATS Exchange. It employs 193 people.Alder Biopharmaceuticals (ALDR) is traded on BATS Exchange in USA. It is located in WASHINGTON U.S.A and employs 193 people. Alder Biopharmaceutica is listed under Pharmaceutical Products category by Fama And French industry classification.

Alder Biopharmaceutica Leadership Team

Erin Lavelle, COO
Xavier GallotLavallee, Member of the Supervisory Board
Deepa Pakianathan, Independent Director
Bruce Montgomery, Independent Director
Anne TrotouxCoppermann, Member of the Supervisory Board
Robert Azelby, President CEO
Christian Viguie, Chairman of the Supervisory Board
Deepika Pakianathan, Independent Director
John Latham, Co-Founder and Chief Scientific Officer
Jeremy Green, Director
Bruno Pavlovsky, Member of the Supervisory Board
Wendy Yarno, Independent Director
Joel Desmaris, Member of the Management Board in Charge of Finance and Investor Relations
Olivier Lambert, Member of the Supervisory Board
Randal Hassler, Senior Vice President Pharmaceutical Operations
Paul Carter, Director
Stephen Dow, Independent Chairman of the Board
Randall Schatzman, Co-Founder, CEO and President and Director
Eric Carter, Interim Chief Medical Officer
Mark Litton, Chief Business Officer, Treasurer and Secretary
Larry Benedict, Sr. VP of Fin.
Pierre Conte, Member of the Supervisory Board
Pierre Tourrette, Vice Chairman of the Supervisory Board
Heather Preston, Independent Director
Jeffrey Smith, Senior Vice President Translational Medicine
Timothy Whitaker, Chief Medical Officer
James Bucher, Senior Vice President General Counsel
Paul Cleveland, Director
Clay Siegall, Independent Director
Frederic Serre, Chairman of the Management Board
Elisabeth Sandoval, Chief Commercial Officer
Philippe Mattia, Member of the Supervisory Board

Stock Performance Indicators

Current Sentiment - ALDR

Alder Biopharmaceutica Investor Sentiment
Most of Macroaxis users are presently bullish on Alder Biopharmaceuticals. What is your sentiment towards investing in Alder Biopharmaceuticals? Are you bullish or bearish?
98% Bullish
2% Bearish

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for Alder Biopharmaceutica and China Cord Blood. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.